Delete search term


Quick navigation

Main navigation

HIT to LEAD to Preclinical Candidate development of a Transcription Repressor Inhibitory Compound (TRIC) that increases antibiotic susceptibility of multidrug resistant staphylococci

At a glance

  • Project leader : Prof. Dr. Rainer Riedl
  • Project team : Dr. Mathieu Chellat, Luka Raguz
  • Project budget : CHF 1'979'276
  • Project status : completed
  • Funding partner : CTI (KTI-Projekt / Projekt Nr. 15235.1 PFLS-LS)
  • Project partner : BioVersys AG
  • Contact person : Rainer Riedl


A new and highly innovative treatment will be realized by a novel and patentable small molecule combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic staphylococci. The consortium integrates a screening platform, biophysical characterization of small molecules, medicinal chemistry, high-end characterization of mode of action and the in vivo mouse models, to develop initial HIT compounds into preclinical candidates.